A hospital-based rnulticentric study results on gestational trophoblastic disease management status in a developing country

Objective: To determine the clinical management of gestational trophoblastic disease in Turkey.

Material and methods: An inquiry form was sent to 55 health centers including university hospitals, maternity hospitals with residency programs and maternity hospitals without residency programs in 1997. The inquiry consisted of questions about the type of classification systems in use, distribution of cases according to those classifications, use of prophylactic chemotherapy and its indications, and drug preference for single-agent or combined chemotherapies.

Results: The overall response rate to the conducted inquiry was 47.1%. A clinical classification system was identified in 60% of the hospitals in Turkey. Generally, methotrexate was the most used single-agent chemotherapy. With regard to first-line combined chemotherapy, MAC (methotrexate, antinomycin-D, cyclophosphamide) was the preferred combination. EMA-CO (etoposide, methotrexate, actinomycin-D, cyclophosphamide, vincristine) was the most common used second-line chemotherapeutic regimen.

Conclusion: Due to insufficient data acquisition from all the medical centers and a lack of national population-based studies, it is difficult to draw a conclusion with respect to the interpretation of the data about the management protocols of gestational trophoblastic disease.

Gestational trophoblastic disease; Management; Hospital-based study

[1] Semer D. A., Macfee M. S.: "Gestational trophoblastic disease: epidemiology". Seminars in Oncology, 1995, 22 (2), 109.

[2] Hammond C. B., Borchert L. G., Tyreyl L. et al.: "Treatment of metastatic trophoblastic diseases: good and poor prognosis". Am. J. Obstet. Gynecol., 1973, 115, 454.

[3] Berkowitz R. S., Goldstein D. P.: "Gestational trophoblastic disease". In: Berek J. S. (ed.): "Novak's Gynecology". Twelfth edition, Williams and Wilkins, Baltimore 1996, 1261.

[4] Gestational trophoblastic disease: "WHO technical report senes 692". WHO Geneva 1983.

[5] Smith D. B.,N ewslands E. S.,H olden L.,B agshawe K. D.: "Correlation between clinical staging and FIGO staging groups with gestational trophoblastic disease". Br. J. Obstet. Gynaecol., 1993, 100, 157.

[6] Goldstein D. P., Zanten Przybysz I. V., Bernstein M. R., Berkowitz R. S.: "Revised FIGO staging system for gestational trophoblastic tumours; recommendations regarding therapy". J. Reprod. Med., 1998, 43, 37.

[7] Kohorn E. I.: "Assessing and staging of trophoblastic tumors". Trophoblastic Disease Update, 1998, 2, 3.

[8] Hanconck B. W., Welch E. M., Gillespie A. M., Newslands E. S.: "A retrospective comparison of current and proposed staging and scoring systems for persistent gestational trophoblastic disease". Int. J. Gynecol. Cancer, 2000, 10, 318.

[9] Gillespie A. M., Kumar S., Hancock B. W.: "Treatment of persistent trophoblastic disease later than 6 months after diagnosis of molar pregnancy". Br. J. Cancer, 2000, 82 (8), 1393.

[10] Bagshawe K. D., Begent R. H. J., Rustin G. J. S., Brock C., Short D., Holden L. et al.: "EMNCO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients". J. Clin. Oncol., 1997, 15, 2636.

[11] Hancock B. W., Coleman R. E., Lorigan P. C., Dobson L. S.: "Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide,d actinomycin) as first-line chemotherapy in highrisk disease and EA (etoposide and dactinomycin) as second-line therapy for low-risk disease". Br. J. Cancer, 2000, 82 (9), 1547.

[12] Rustin G. J. S., Seckl M. J., Holden L., Mulholland P. J., Newslands E. S.: "Etoposide and cisplatin/etoposide, and actinomycinD (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMNCO chemotherapy and patients presenting with metastatic placental site trophoblastic tumors". J. Clin. Oncol., 2000, 18, 854.